Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Janssen Research & Development, LLC
BeOne Medicines
Merck Sharp & Dohme LLC
Tyra Biosciences, Inc
Memorial Sloan Kettering Cancer Center
Inhibrx Biosciences, Inc
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
OncoC4, Inc.
Klus Pharma Inc.
Cybrexa Therapeutics
Salubris Biotherapeutics Inc